Isolated relapse of plasma cell leukemia in the central nervous systems: a case report and literature review

被引:0
作者
Takafumi Obo
Ken Morita
Yutaro Sumida
Kumi Nakazaki-Watadani
Masako Ikemura
Koichiro Yasaka
Osamu Abe
Hirokazu Takami
Shunsaku Takayanagi
Shota Tanaka
Hiroaki Maki
Yosuke Masamoto
Akiyoshi Miwa
Mineo Kurokawa
机构
[1] The University of Tokyo,Department of Hematology & Oncology, Graduate School of Medicine
[2] The University of Tokyo,Department of Pathology, Graduate School of Medicine
[3] The University of Tokyo,Department of Radiology, Graduate School of Medicine
[4] The University of Tokyo,Department of Neurosurgery, Graduate School of Medicine
[5] Tokyo-Kita Medical Center,Department of Hematology
来源
International Journal of Hematology | 2023年 / 118卷
关键词
Plasma cell leukemia; Multiple myeloma; Extramedullary plasmacytoma; Central nervous system;
D O I
暂无
中图分类号
学科分类号
摘要
Plasma cell leukemia is a rare yet aggressive form of multiple myeloma characterized by high levels of plasma cells circulating in the peripheral blood. We recently experienced a case of plasma cell leukemia that had been in stringent complete remission for nine years after autologous stem cell transplantations with subsequent courses of lenalidomide maintenance therapy, and then relapsed as an extramedullary plasmacytoma in the central nervous system. Assessment of the bone marrow did not prove proliferation of plasma cells at relapse, but imbalanced elevation of serum levels of free light chains was observed without changes in other clinical biomarkers including immunoglobulin levels. Salvage chemotherapy with isatuximab, pomalidomide, and dexamethasone (IsaPD) was promptly initiated. After two courses of IsaPD, significant remission was achieved and the neuronal symptoms completely resolved. When excessive serum levels of clonotypic free light chains are noted, their significance should be carefully assessed even when plasma cell propagation in the bone marrow is not observed. In such cases, hematologists should search for extramedullary proliferation of plasma cells, including in the immune-privileged central nervous system.
引用
收藏
页码:135 / 140
页数:5
相关论文
共 67 条
  • [1] Fernandez de Larrea C(2021)Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage Blood Cancer J 11 192-2672
  • [2] Kyle R(2021)Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment Leuk Res 111 106687-232
  • [3] Rosinol L(2021)A clinical perspective on plasma cell leukemia; current status and future directions Blood Cancer J 11 23-18
  • [4] Paiva B(2022)Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features Blood 139 2666-477
  • [5] Engelhardt M(2015)Comparison of (11)C-4'-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma Ann Nucl Med 29 224-1417
  • [6] Usmani S(2001)Henry Bence Jones–physician, chemist, scientist and biographer: a man for all seasons Br J Haematol 115 13-866
  • [7] Gowin K(2022)Diagnosis and management of multiple myeloma: a review JAMA 327 464-309
  • [8] Skerget S(2013)Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models PLoS ONE 8 e71754-896
  • [9] Keats JJ(2015)Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010–02 trial results Blood 125 1411-undefined
  • [10] Mikhael J(2013)Effective treatment of pomalidomide in central nervous system myelomatosis Leuk Lymphoma 54 864-undefined